<DOC>
	<DOCNO>NCT00121316</DOCNO>
	<brief_summary>This study conduct United States . Patients intolerant topical corticosteroid ( TCS ) either experienced adverse event result use TCS , require unacceptable level exposure TCS order control AD . This particular concern patient recurrent flare delicate skin area head neck . The purpose study investigate whether pimecrolimus cream 1 % , non-steroidal anti-inflammatory drug , efficacious treat mild moderate head neck AD patient intolerant , dependent topical corticosteroid .</brief_summary>
	<brief_title>Safety Efficacy Pimecrolimus Cream 1 % Mild Moderate Head Neck Atopic Dermatitis ( AD ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>12 year age old Mild moderate facial AD screening ( facial IGA 2 3 ) Patients intolerant , dependent , topical corticosteroid Diagnosis atopic dermatitis Hanifin Rajka criterion For female patient , negative pregnancy test . Women pregnant breastfeeding may include study . Women childbearing potential must follow medically recognize form contraception . At baseline throughout study , patient : Who AD great 30 % total body surface area addition facial eczema Who concurrent skin disease ( e.g . acne ) study area active skin infection ( active bacterial , viral fungal infection infestation , herpes simplex , herpes zoster , chicken pox ) , condition may interfere evaluation ( e.g . generalize erythroderma , Netherton 's syndrome ) Who immunocompromised ( e.g . Lymphoma , AIDS , WiskottAldrich Syndrome ) history malignant disease ( exception treat basalcell carcinoma ) Who previously report poor , clinical response , hypersensitivity topical pimecrolimus cream ( Elidel ) Who receive phototherapy ( e.g . UVA , UVB ) systemic therapy ( e.g.immunosuppressants , corticosteroid , cytostatics ) know suspected effect AD within 4 week Visit 2 Who receive investigational drug within 8 week first application study drug plan use investigational drug participation study Who unlikely comply therapy</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Atopic dermatitis</keyword>
	<keyword>pimecrolimus</keyword>
</DOC>